Aciphin (Inj) 1gm vial

Aciphin 1g IV Injection — Ceftriaxone 1000mg Intravenous

1. Indications

Aciphin® 1g IV is the standard adult dose formulation of ceftriaxone — a third-generation cephalosporin antibiotic for once-daily parenteral treatment of moderate to severe bacterial infections. Indications include: lower respiratory tract infections (community-acquired pneumonia, hospital-acquired pneumonia, acute exacerbations of COPD); complicated and uncomplicated urinary tract infections and pyelonephritis; septicaemia and bacteraemia; skin, soft tissue, bone and joint infections; intra-abdominal infections (peritonitis, biliary tract infections); bacterial meningitis (2g dose may be preferred); uncomplicated gonorrhoea; pelvic inflammatory disease; ENT infections; acute bacterial otitis media; surgical prophylaxis (single 1–2g pre-operative dose); typhoid and paratyphoid fever; and infections in immunocompromised patients.

Diabetes relevance: Aciphin® 1g IV is a cornerstone treatment for hospitalised diabetic patients — diabetic foot infections (DFI), complicated UTIs (pyelonephritis), community-acquired pneumonia, and bacteraemia. Its unique dual hepatic-renal elimination profile means standard 1g once-daily dosing can be maintained in most patients with diabetic nephropathy until CrCl falls below 10 ml/min.

2. Mechanism of Action

Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs 1a, 1b, 2, 3), preventing peptidoglycan cross-linking and causing osmotic lysis. Bactericidal. Active against beta-lactamase producers. Broad Gram-positive and Gram-negative spectrum: Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae & meningitidis, Proteus mirabilis, Salmonella typhi, Staphylococcus aureus (MSSA).

3. Dosage & Administration

Standard adult dose: 1–2g IV once daily (every 24h). Severe infections / meningitis: 2–4g/day. Surgical prophylaxis: 1–2g single pre-operative dose.
Children (15 days–12 years): 20–80 mg/kg/day; 100 mg/kg/day in life-threatening infections.
IV Reconstitution: Dissolve 1g in 10ml Water for Injection BP. Give by slow IV push over minimum 5 minutes (pack contains butterfly needle), or dilute in 50–100ml 0.9% NaCl / 5% dextrose for 30-minute infusion.
Renal impairment: No adjustment needed if CrCl >10 ml/min. Max 2g/day in severe renal failure (CrCl <10). No adjustment for hepatic impairment if renal function intact.
Duration: 4–14 days depending on infection. Continue 2–3 days after symptom resolution.

4. Side Effects

Generally well tolerated. GI: nausea, vomiting, diarrhoea (2–4%). Clostridioides difficile-associated diarrhoea possible. Haematological: eosinophilia, thrombocytosis/thrombocytopenia, leucopaenia. Hepatic: transient elevated ALT/AST. Biliary sludge/pseudolithiasis — particularly in children, reversible. IV site: phlebitis, pain. Hypersensitivity: rash, urticaria; anaphylaxis (rare; cross-react with penicillin ~1–2%). CRITICAL: Fatal precipitation with calcium-containing IV solutions — never co-administer.

5. Contraindications

Hypersensitivity to ceftriaxone or cephalosporins; history of penicillin anaphylaxis; hyperbilirubinaemic or premature neonates; concurrent calcium-containing IV solutions in neonates.

6. Warnings & Precautions

Screen for penicillin/cephalosporin allergy before administration; keep epinephrine available. Monitor for CDAD if diarrhoea occurs. Never co-administer with Ringer's Lactate, Hartmann's or any calcium-containing IV fluid. For diabetic nephropathy patients with CrCl <10 ml/min, cap dose at 2g/day and monitor closely.

7. Drug Interactions

Aminoglycosides: synergistic (use separate IV lines, do not mix). Warfarin: potentiation reported (monitor INR closely). Calcium-containing IV solutions: CONTRAINDICATED — fatal precipitate. Probenecid: no clinically significant effect on ceftriaxone. NSAIDs: may increase risk of bleeding.

8. Pharmacokinetics

100% IV bioavailability. Protein binding 85–95%. Half-life 6–9h. Dual elimination: ~50% renal (unchanged), ~50% biliary (unchanged). Volume of distribution: 7–12L. Excellent CSF, bone, lung, and peritoneal penetration. Safe in renal impairment — biliary backup maintains therapeutic levels. No dialysis clearance.

9. Storage

Store below 30°C, protected from light and moisture. Reconstituted solution stable 6h at room temperature (25°C), 24h at 2–8°C. Use immediately after reconstitution when possible. Discard unused portion.

10. Course Completion

Complete the full prescribed course even if symptoms improve. Premature discontinuation risks treatment failure and antibiotic resistance. Typical minimum duration: 5–7 days for uncomplicated infections; 10–14 days for typhoid, bone infections, or meningitis.

11. Overdose

No specific antidote. Ceftriaxone is not removed by haemodialysis or peritoneal dialysis. Management is supportive. Neurological monitoring advised at high doses.

12. Clinical Evidence

WHO Essential Medicine. Standard of care for community-acquired pneumonia (IDSA/BTS guidelines), bacterial meningitis (WHO/NICE), typhoid fever, complicated UTI, and sepsis management worldwide. Once-daily dosing clinically equivalent to multiple-daily dosing (Lancet, multiple RCTs). In Bangladeshi hospitals, the most commonly prescribed IV antibiotic for diabetic foot infection co-infections and MDR typhoid.

13. Patient Counselling

Healthcare professional administration required. Report immediately: skin rash, breathing difficulty, facial swelling (allergy). Report diarrhoea — may indicate antibiotic-associated colitis. This IV pack contains Water for Injection (NOT lidocaine). Do not use this pack for intramuscular injection — separate IM kits with Xylone 1% solvent are available. Complete the full antibiotic course.

Frequently Asked Questions (FAQ)

Q1. Is 1g once daily sufficient for serious infections in adults?
For most adult infections — pneumonia, UTI, skin/soft tissue, typhoid — 1g once daily is the standard effective dose. For bacterial meningitis or severe sepsis, 2g once daily or 2g every 12h is preferred. Once-daily dosing is supported by multiple clinical trials and international guidelines as equivalent to twice-daily regimens for most indications.

Q2. Can ceftriaxone 1g be given as an IV infusion instead of bolus?
Yes — after reconstitution in 10ml Water for Injection BP, dilute further in 50–100ml of 0.9% NaCl or 5% Dextrose and infuse over 30 minutes. For IV bolus, administer over minimum 5 minutes. The Aciphin 1g IV pack includes a butterfly needle to facilitate slow IV push. Always use a separate IV line — never co-administer with calcium-containing fluids.

Q3. How does ceftriaxone work in patients with diabetic kidney disease?
Ceftriaxone has a unique dual elimination pathway — approximately 50% renal and 50% biliary. This means the liver compensates when kidneys are impaired. For most diabetic patients (CrCl >10 ml/min), standard 1g once-daily dosing requires no adjustment. Only in severe renal failure (CrCl <10 ml/min) is the maximum dose capped at 2g/day. This makes ceftriaxone considerably safer in diabetic nephropathy than aminoglycosides or carbapenems.

Q4. What is the difference between Aciphin 1g IV and Aciphin 1g IM?
Both contain ceftriaxone 1g but differ critically in reconstitution and route. The IV pack contains 10ml Water for Injection BP (butterfly needle, 10ml syringe) for intravenous administration. The IM pack contains 3.5ml Xylone 1% (lidocaine hydrochloride 1%) for deep intramuscular injection only. The lidocaine-reconstituted IM solution must NEVER be given intravenously — it causes cardiac arrhythmia and toxicity. Always verify which pack you have before administration.

⚕ Medical Disclaimer: Aciphin® 1g IV is a prescription parenteral antibiotic for administration by trained healthcare professionals only. Information sourced from ACI Pharmaceuticals Ltd. official prescribing data and WHO guidelines. Educational purposes only.